Provided by Tiger Fintech (Singapore) Pte. Ltd.

Applied DNA Sciences

0.9000
+0.090011.11%
Post-market: 0.8930-0.0070-0.78%19:58 EDT
Volume:2.11M
Turnover:1.91M
Market Cap:5.85M
PE:-0.01
High:0.9489
Open:0.8300
Low:0.8060
Close:0.8100
Loading ...

Applied DNA Sciences Advances in Genetic Medicines Market

TIPRANKS
·
13 Jan

Applied DNA completes buildout of GMP facility for LineaDNA IVT templates

TIPRANKS
·
10 Jan

Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates

ACCESSWIRE
·
10 Jan

Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter

ACCESSWIRE
·
09 Jan

Applied DNA customer UHKT initiates Phase I clinical trial of UHKT-CAR123-01

TIPRANKS
·
18 Dec 2024

Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA

ACCESSWIRE
·
18 Dec 2024

Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket

Benzinga
·
18 Dec 2024

General Mills, Micron Technology And 3 Stocks To Watch Heading Into Wednesday

Benzinga
·
18 Dec 2024

Applied DNA Sciences (APDN) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
18 Dec 2024

Applied DNA Sciences Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
18 Dec 2024

BRIEF-Applied Dna Sciences Inc - Pursuing Divestiture Of Certaint Platform, Implements Changes To Corporate Leadership

Reuters
·
18 Dec 2024

Applied DNA Sciences Announces Leadership Changes and Restructuring

TIPRANKS
·
18 Dec 2024

Applied DNA Sciences: Fiscal Q4 Earnings Snapshot

Associated Press Finance
·
18 Dec 2024

Applied DNA Sciences Q4 2024 GAAP EPS $(0.32) Beats $(0.34) Estimate, Sales $813.11K Miss $899.00K Estimate

Benzinga
·
18 Dec 2024

Applied DNA Sciences Inc - Net Loss for Q4 of Fiscal 2024 Was $0.32 per Share

THOMSON REUTERS
·
18 Dec 2024

Applied DNA Sciences Inc - Pursuing Divestiture of Certaint Platform, Implements Changes to Corporate Leadership

THOMSON REUTERS
·
18 Dec 2024

Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines

ACCESSWIRE
·
18 Dec 2024

Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out

ACCESSWIRE
·
16 Dec 2024

Applied DNA Sciences Inc expected to post a loss of 34 cents a share - Earnings Preview

Reuters
·
14 Dec 2024

Applied DNA Sciences Inc expected to post a loss of 34 cents a share - Earnings Preview

Reuters
·
11 Dec 2024